Yseop is a generative AI specialist focused on life sciences, offering an enterprise platform that automates the writing of complex documents such as clinical study reports, patient narratives and CMC submissions. Its flagship product, Yseop Copilot, is already deployed at major pharmaceutical companies including Eli Lilly and Novartis. The system uses a Composite AI architecture that blends large language models with business logic and domain rules to deliver scientifically aligned, audit-ready content. Native integrations with Microsoft Word and Veeva Vault let users embed automation directly into existing workflows, accelerating document production while maintaining compliance. With regulatory demands growing, the company sees rising demand for intelligent automation across the sector. The newly secured funding will be used to scale global adoption, enhance product capabilities and accelerate innovation. Although detailed operating metrics such as revenue were not disclosed, the presence of blue-chip customers underscores early commercial traction.

Total raised

$21M

Funding rounds

3

Latest round

Equity

Latest activity

Oct 2025